ATLANTA, Feb. 18, 2025 ( GLOBE NEWSWIRE ) -- A shareholder class action lawsuit has been filed against TransMedics Group, Inc. ( "TransMedics" or the "Company" ) TMDX. The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material ...

Predictive Oncology reported positive results from utilizing artificial intelligence for drug repurposing. Get two weeks of free access to pro-level trading tools, including news alerts, scanners, and real-time market insights. Predictive Oncology, Inc.

Rekor secures a European patent for its AI-driven system that detects and manages irregular traffic congestion in real time. The patented technology integrates machine learning with historical data to optimize traffic flow and respond to real-time disruptions.

Watsco exceeded expectations with impressive Q4 2024 results, showcasing strong sales growth and strategic technological strides.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Morgan Stanley analyst Craig Hettenbach downgraded the rating for Hims & Hers Health, Inc.

VIRGINIA BEACH, Va., Feb. 18, 2025 ( GLOBE NEWSWIRE ) -- Resurgent Realty Trust ( "RRT" ) , a shareholder of Generation Income Properties, Inc. GIPR ( "GIPR" or the "Company" ) , issued today an open letter containing a non-binding term sheet RRT submitted to GIPR's Board of Directors ( the ...

TORONTO, Feb. 18, 2025 /CNW/ - Dynamic Funds today announced the February 2025 cash distributions for the Dynamic Active ETFs and ETF series units of certain Dynamic Funds ( ETF Series ) listed on the TSX, which pay on a monthly basis.

Ares Management ARES has outperformed the market over the past 5 years by 23.11% on an annualized basis producing an average annual return of 36.7%. Currently, Ares Management has a market capitalization of $38.16 billion.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Genuine Parts Q4 revenue and adjusted EPS both beat estimates. Genuine Parts sees FY25 adjusted EPS of $7.75 - $8.25, below $8.29 estimate. Get access to your new suite of high-powered trading tools, including real-time stock ratings, insider trades, and government trading signals.